Ulcerative Colitis (Moderate to Severe) | DecisionBase | US/EU5 | 2014
Amid significant unmet need, what attributes do gastroenterologists and payers expect of a therapy with a mechanism of action different from that of the currently available TNF-alpha inhibitors?
Significant opportunity remains for therapies that target the moderate to severe UC population, particularly for emerging drugs with novel mechanisms of action that can more effectively achieve mucosal healing and maintain long-term disease remission relative to the leading TNF-α inhibitor, infliximab. Current therapies for moderate to severe UC are associated with insufficient efficacy, sometimes serious safety concerns, and a high burden of delivery. With the cell adhesion molecule (CAM) inhibitor vedolizumab (Takeda’s Entyvio) and the oral Janus-activated kinase (Jak) inhibitor tofacitinib (Pfizer’s Xeljanz) in late-stage development for UC, the competition in the TNF-refractory space is intensifying as companies battle to differentiate their novel therapies and capture market share.
